Home Cart Sign in  
Chemical Structure| 1510-21-0 Chemical Structure| 1510-21-0
Chemical Structure| 1510-21-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Synonyms: Cholesterol hydrogen succinate; Cholesteryl hydrogen succinate

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Cholesteryl Hemisuccinate

CAS No. :1510-21-0
Formula : C31H50O4
M.W : 486.73
SMILES Code : O=C(O)CCC(O[C@H]1CC[C@]2(C)[C@@]3([H])CC[C@]4(C)[C@@H]([C@@H](CCCC(C)C)C)CC[C@@]4([H])[C@]3([H])CC=C2C1)=O
Synonyms :
Cholesterol hydrogen succinate; Cholesteryl hydrogen succinate
MDL No. :MFCD00037705
InChI Key :WLNARFZDISHUGS-MIXBDBMTSA-N
Pubchem ID :65082

Safety of Cholesteryl Hemisuccinate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Application In Synthesis of Cholesteryl Hemisuccinate

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 1510-21-0 ]

[ 1510-21-0 ] Synthesis Path-Downstream   1~4

  • 1
  • [ 623-57-4 ]
  • [ 1510-21-0 ]
  • [ 926890-44-0 ]
  • [ 2387-23-7 ]
YieldReaction ConditionsOperation in experiment
34% With dicyclohexyl-carbodiimide; In dichloromethane; at 0 - 20℃; for 6.25h;Product distribution / selectivity; To a solution of 3-dimethylamino-l,2-propanediol (0.5g, 3,6 mmoles) in 10 mL dichloromethane was added cholesterylhemisuccinic acid (1.75g, 3.6 mmoles) and DCC (1.48g, 7.2 mmoles) at 0°C. The reaction was allowed to proceed from 0°C (15 mins) to room temperature for 6 hours. DCU was filtered off and the filtrate was evaporated on a rotary evaporator and loaded on a silica gel (230-400 mesh). The desired product was EPO <DP n="57"/>eluted with 4-5percent methanol in chloroform (v/v) to give a colorless thick liquid (0.834g, Rf -0.5 in 10percent methanol in chloroform, yield 34percent).1HNMR (400 MHz, CDCl3): delta 5.36 (d, J= 4.0 Hz, IH), 4.67-4.56 (m, IH), 4.19 (dd, J= 11.6, 3.6 Hz, IH), 4.04 (dd, J= 11.6, 6.0 Hz, IH), 3.97-3.89 (m, IH), 2.70-2.56 (m, 4H), 2.44 (t, J= 10.0 Hz, IH), 2.36-2.23 (m, 9H), 2.05-1.75 (m, 5H), 1.66-0.80 (m, 33H), 0.67 (s, 3H).
34% With dicyclohexyl-carbodiimide; In N,N-dimethyl-formamide; at 0 - 20℃; for 6.08333h;Product distribution / selectivity; An alternative synthesis procedure is as follows: to an ice-cooled solution of cholesteryl hemisuccinate (4.09 g, 8.42 mmol) in DMF (35 mL) 3-(dimethylamino)-l,2- propandiol (1.0 mL, 8.42 mmol) was added N,N'-dicyclohexylcarbodiimide (3.47 g, 16.84 mmol). After 5 min., the ice bath was removed and the solution was stirred for an additional 6 h at room temperature. The resulting precipitation of dicyclohexylurea was removed by filtration. The filtrate was transferred to a 100 mL round bottom flask and concentrated to dryness under vacuum. The pasty mass was dissolved in CHCl3 (200 mL) and washed with H2O (30 mL), saturated aqueous NaCl (30 mL), dried (Na2SO4) and concentrated in vacuo. Purification by column chromatography (SiO2, elution with 5percent MeOH in CHCl3) furnished IV (1.68 g, 34percent) as wax. NMR spectra coordinates are as follows: 1H NMR (CDCl3): delta 5.36 (d, J= 4.0 Hz, IH), 4.67-4.56 (m, IH), 4.19 (dd, J = 11.6, 3.6 Hz, IH), 4.04 (dd, J= 11.6, 6.0 Hz, IH), 3.97-3.89 (m, IH), 2.70-2.56 (m, 4H), 2.44 (t, J= 10.0 Hz, IH), 2.36-2.23 (m, 9H), 2.05-1.75 (m, 5H), 1.66-0.80 (m, 33H), 0.67 (s, 3H).
  • 2
  • [ 349-58-6 ]
  • [ 1510-21-0 ]
  • [ 1015228-56-4 ]
YieldReaction ConditionsOperation in experiment
46% With dmap; In dichloromethane; at 20℃; Preparation of Compound b4-2; Cholesterol succinate (0.98 g) was dissolved in dichloromethane (5 mL). The mixture was added with 3,5-bis(trifluoromethyl) phenol (0.55 g), 4-(dimethylamino)pyridine (28 mg), and WSC (Dojindo)(0.52 g), and stirred at room temperature. The reaction solution was added with water, and extracted twice with dichloromethane. The resulting organic layer was washed with saturated brine. After the organic layer was dried over anhydrous magnesium sulfate, the solvent was removed and the residue was purified by silica gel column chromatography to obtain Compound b4-2 (0.64g, 46percent). 1H-NMR (300MHz, CDCl3) delta : 7.76 (1H, s), 7.61 (2H, s), 5.37 (1H, d), 4.73-4.60(1H, m), 2.91 (2H, dd), 2.74 (2H, dd), 2.33 (2H, d), 2.28(2H, t), 2.10-0.80 (38H, m), 0.70 (3H, s).
  • 3
  • [ 623-57-4 ]
  • [ 1510-21-0 ]
  • [ 926890-44-0 ]
YieldReaction ConditionsOperation in experiment
Synthesis ofl. Cholesteryl hemisucciriate (3 g, MW 486.2) and N, N- dimethylaminopropanediol (0.73 g, MW 120) were combined in 50 mL CH2CI2 and stirred until dissolved. Next, 0.5 g DMAP and 2.2 g of DCC were added sequentially to the reaction and it was stirred for 10 h. The reaction was then vacuum-filtered to remove the precipitated DCU. The filtrate was dried by rotary evaporation. The white solid was taken up into chloroform and purified on a Horizon Flash Chromatography system with achloroform/methanol elution system (0-3percent MeOH over 360 mL, 9mL/fraction). The product was collected with minor impurities in fractions 45-60 and moved on to the next step.
  • 4
  • [ 1510-21-0 ]
  • [ 97682-44-5 ]
  • C33H38N4O6*C31H50O4 [ No CAS ]
YieldReaction ConditionsOperation in experiment
In chloroform; for 1.5h;Cooling with ice; Weigh <strong>[97682-44-5]irinotecan</strong> hydrochloride,Add an appropriate amount of ultrapure water, stir into a slurry, and add 1 mol/L NaHCO3 solution dropwise, wherein the weighed <strong>[97682-44-5]irinotecan</strong> hydrochloride and NaHCO3 are in an equimolar ratio; stirring is continued until the reaction is complete. After centrifugation, the supernatant was discarded, and the precipitate was washed 2 to 3 times with ultrapure water, and the precipitate was collected. Dry at 40 ° C for 2 h under vacuum. The finally obtained white powder is <strong>[97682-44-5]irinotecan</strong> free base, stored in a vial, and stored in a refrigerator at 4 ° C in the dark. The equimolar ratio of <strong>[97682-44-5]irinotecan</strong> free base and cholesterol succinic acid monoester was dissolved in an appropriate amount of chloroform solution, stirred in an ice bath for 1.5 h, and the anti-solvent methyl tert-butyl ether was added dropwise thereto.The turbidity was stopped, the solvent was naturally evaporated in a hood, and dried in a vacuum oven at 40 ° C for 2 h. The finally obtained pale yellow powder is an <strong>[97682-44-5]irinotecan</strong>-cholesteryl succinate monoester ion pair and stored in a vial.Keep the refrigerator at 4 °C in the dark.
 

Historical Records

Categories